294 related articles for article (PubMed ID: 31220365)
1. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial.
Merlijn T; Swart KM; van Schoor NM; Heymans MW; van der Zwaard BC; van der Heijden AA; Rutters F; Lips P; van der Horst HE; Niemeijer C; Netelenbos JC; Elders PJ
J Bone Miner Res; 2019 Nov; 34(11):1993-2000. PubMed ID: 31220365
[TBL] [Abstract][Full Text] [Related]
2. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis.
Merlijn T; Swart KMA; van der Horst HE; Netelenbos JC; Elders PJM
Osteoporos Int; 2020 Feb; 31(2):251-257. PubMed ID: 31838551
[TBL] [Abstract][Full Text] [Related]
3. Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study.
McCloskey E; Johansson H; Harvey NC; Shepstone L; Lenaghan E; Fordham R; Harvey I; Howe A; Cooper C; Clarke S; Gittoes N; Heawood A; Holland R; Marshall T; O'Neill TW; Peters TJ; Redmond N; Torgerson D; Kanis JA;
J Bone Miner Res; 2018 Jun; 33(6):1020-1026. PubMed ID: 29480960
[TBL] [Abstract][Full Text] [Related]
4. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.
Shepstone L; Lenaghan E; Cooper C; Clarke S; Fong-Soe-Khioe R; Fordham R; Gittoes N; Harvey I; Harvey N; Heawood A; Holland R; Howe A; Kanis J; Marshall T; O'Neill T; Peters T; Redmond N; Torgerson D; Turner D; McCloskey E;
Lancet; 2018 Feb; 391(10122):741-747. PubMed ID: 29254858
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study.
Rubin KH; Rothmann MJ; Holmberg T; Høiberg M; Möller S; Barkmann R; Glüer CC; Hermann AP; Bech M; Gram J; Brixen K
Osteoporos Int; 2018 Mar; 29(3):567-578. PubMed ID: 29218381
[TBL] [Abstract][Full Text] [Related]
6. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
7. Screening for high hip fracture risk does not impact on falls risk: a post hoc analysis from the SCOOP study.
Condurache CI; Chiu S; Chotiyarnwong P; Johansson H; Shepstone L; Lenaghan E; Cooper C; Clarke S; Khioe RFS; Fordham R; Gittoes N; Harvey I; Harvey NC; Heawood A; Holland R; Howe A; Kanis JA; Marshall T; O'Neill TW; Peters TJ; Redmond NM; Torgerson D; Turner D; McCloskey E;
Osteoporos Int; 2020 Mar; 31(3):457-464. PubMed ID: 31960099
[TBL] [Abstract][Full Text] [Related]
8. Decreased Mortality and Subsequent Fracture Risk in Patients With a Major and Hip Fracture After the Introduction of a Fracture Liaison Service: A 3-Year Follow-Up Survey.
Vranken L; de Bruin IJA; Driessen AHM; Geusens PPM; Eisman JA; Center JR; van der Velde RY; Janzing HMJ; Kaarsemaker S; van den Bergh JP; Wyers CE
J Bone Miner Res; 2022 Oct; 37(10):2025-2032. PubMed ID: 36087016
[TBL] [Abstract][Full Text] [Related]
9. Repeat bone mineral density screening and prediction of hip and major osteoporotic fracture.
Berry SD; Samelson EJ; Pencina MJ; McLean RR; Cupples LA; Broe KE; Kiel DP
JAMA; 2013 Sep; 310(12):1256-62. PubMed ID: 24065012
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of osteoporosis screening strategies for hip fracture prevention in older Chinese people: a decision tree modeling study in the Mr. OS and Ms. OS cohort in Hong Kong.
Su Y; Lai FTT; Yip BHK; Leung JCS; Kwok TCY
Osteoporos Int; 2018 Aug; 29(8):1793-1805. PubMed ID: 29774400
[TBL] [Abstract][Full Text] [Related]
11. Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Viswanathan M; Reddy S; Berkman N; Cullen K; Middleton JC; Nicholson WK; Kahwati LC
JAMA; 2018 Jun; 319(24):2532-2551. PubMed ID: 29946734
[TBL] [Abstract][Full Text] [Related]
12. Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study.
Fu SH; Wang CY; Hung CC; Lee CC; Yang RS; Huang CC; Farn CJ; Lin WH; Chen HM; Hsiao FY; Lin JW; Li CY
J Intern Med; 2021 Dec; 290(6):1194-1205. PubMed ID: 34237171
[TBL] [Abstract][Full Text] [Related]
13. Screening for women with increased risk of fragility fractures in a general female population using digital X-ray radiogrammetry (DXR).
Wilczek ML; Bhatta L; Brumpton BM; Freyschuss B; Brismar TB
Maturitas; 2021 Feb; 144():60-67. PubMed ID: 33358210
[TBL] [Abstract][Full Text] [Related]
14. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway.
Hoff M; Meyer HE; Skurtveit S; Langhammer A; Søgaard AJ; Syversen U; Dhainaut A; Skovlund E; Abrahamsen B; Schei B
Osteoporos Int; 2017 Oct; 28(10):2935-2944. PubMed ID: 28668994
[TBL] [Abstract][Full Text] [Related]
15. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.
Turner DA; Khioe RFS; Shepstone L; Lenaghan E; Cooper C; Gittoes N; Harvey NC; Holland R; Howe A; McCloskey E; O'Neill TW; Torgerson D; Fordham R;
J Bone Miner Res; 2018 May; 33(5):845-851. PubMed ID: 29470854
[TBL] [Abstract][Full Text] [Related]
16. Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older.
Elders PJM; Merlijn T; Swart KMA; van Hout W; van der Zwaard BC; Niemeijer C; Heymans MW; van der Heijden AA; Rutters F; van der Horst HE; Lips P; Netelenbos JC; van Schoor NM
BMC Musculoskelet Disord; 2017 Oct; 18(1):424. PubMed ID: 29078762
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
[TBL] [Abstract][Full Text] [Related]
18. Intensive screening for osteoporosis in patients with hip fracture.
Amar AOS; Hyldstrup L; Nielsen J; Palm H; Jensen JB
Arch Osteoporos; 2019 Jun; 14(1):63. PubMed ID: 31214797
[TBL] [Abstract][Full Text] [Related]
19. The Added Value of SARC-F to Prescreening Using FRAX for Hip Fracture Prevention in Older Community Adults.
Su Y; Woo JW; Kwok TCY
J Am Med Dir Assoc; 2019 Jan; 20(1):83-89. PubMed ID: 30314676
[TBL] [Abstract][Full Text] [Related]
20. Fracture Risk Indices From DXA-Based Finite Element Analysis Predict Incident Fractures Independently From FRAX: The Manitoba BMD Registry.
Leslie WD; Luo Y; Yang S; Goertzen AL; Ahmed S; Delubac I; Lix LM
J Clin Densitom; 2019; 22(3):338-345. PubMed ID: 30852033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
